T cell receptors

A method for treating a patient comprising:

• administering to the patient a non-naturally occurring and/or purified and/or engineered T cell receptor (TCR) having the property of binding to FMNKFIYEI (SEQ ID NO:
• 1) HLA-A2 complex and comprising:
• at least one TCR alpha chain variable domain and at least one TCR beta chain variable domain,
• wherein the alpha chain variable domain comprises at least one of the following sets of CDR sequences:
• CDR1
• DRGSQA
• residues 27 to 32 of SEQ ID NO:
• 6
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 6
• CDR3
• AVNSDS
• residues 90 to 101 of SEQ ID NO:
• 6
• GYALNF
• or
• CDR1
• DRGSQS
• residues 27 to 32 of SEQ ID NO:
• 7
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 7
• CDR3
• AVNSDS
• residues 90 to 101 of SEQ ID NO:
• 7
• SYALNF
• or
• CDR1
• DRGSQS
• residues 27 to 32 of SEQ ID NO:
• 8
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 8
• CDR3
• AVNSDS
• residues 90 to 101 of SEQ ID NO:
• 8
• GVALNF
• or
• CDR1
• DRGSQA
• residues 27 to 32 of SEQ ID NO:
• 9
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 9
• CDR3
• AVNSDS
• residues 90 to 101 of SEQ ID NO:
• 9
• GVALNF
• or
• CDR1
• DRGSQS
• residues 27 to 32 of SEQ ID NO:
• 10
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 10
• CDR3
• AVNSQS
• residues 90 to 101 of SEQ ID NO:
• 10
• GYALNF
• or
• CDR1
• DRGSQS
• residues 27 to 32 of SEQ ID NO:
• 11
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 11
• CDR3
• AVNSQS
• residues 90 to 101 of SEQ ID NO:
• 11
• GYSLNF
• or
• CDR1
• DRGSQS
• residues 27 to 32 of SEQ ID NO:
• 12
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 12
• CDR3
• AVNSQS
• residues 90 to 101 of SEQ ID NO:
• 12
• SYALNF
• or
• CDR1
• DRGSQA
• residues 27 to 32 of SEQ ID NO:
• 13
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 13
• CDR3
• AVNSQS
• residues 90 to 101 of SEQ ID NO:
• 13
• GYALNF
• or
• CDR1
• DRGSQS
• residues 27 to 32 of SEQ ID NO:
• 14
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 14
• CDR3
• AVNSQS
• residues 90 to 101 of SEQ ID NO:
• 14
• GVALNF
• or
• CDR1
• DRGSQS
• residues 27 to 32 of SEQ ID NO:
• 15
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 15
• CDR3
• AVNSQN
• residues 90 to 101 of SEQ ID NO:
• 15
• GYALNF
• or
• CDR1
• DRGSFS
• residues 27 to 32 of SEQ ID NO:
• 16
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 16
• CDR3
• AVNSDS
• residues 90 to 101 of SEQ ID NO:
• 16
• GYALNF
• or
• CDR1
• DRGSYS
• residues 27 to 32 of SEQ ID NO:
• 17
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 17
• CDR3
• AVNSDS
• residues 90 to 101 of SEQ ID NO:
• 17
• GYALNF
• or
• CDR1
• DRGSYS
• residues 27 to 32 of SEQ ID NO:
• 18
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 18
• CDR3
• AVNSDS
• residues 90 to 101 of SEQ ID NO:
• 18
• SYALNF
• or
• CDR1
• DRGSYS
• residues 27 to 32 of SEQ ID NO:
• 19
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 19
• CDR3
• AVNSDS
• residues 90 to 101 of SEQ ID NO:
• 19
• GVALNF
• or
• CDR1
• DRGSYS
• residues 27 to 32 of SEQ ID NO:
• 20
• CDR2
• IYSNGD
• residues 50 to 55 of SEQ ID NO:
• 20
• CDR3
• AVNSQS
• residues 90 to 101 of SEQ ID NO:
• 20
• GYALNF
• and the wherein the beta chain variable domain comprises the following set of CDR sequences:
• CDR1
• SGDLS
• residues 27 to 31 of SEQ ID NO:
• 5
• CDR2
• YYNGEE
• residues 49 to 54 of SEQ ID NO:
• 5
• CDR3
• ASSLGGES
• residues 92 to 102 of SEQ ID NO:
• 5
• EQF